{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-22-000132","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.899203+00:00","generated_at":"2026-06-24T01:46:04.257658+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO","bullets":["Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).","Adjusted EBITDA negative $16M vs positive $5M in Q2 2021; adjusted net loss $20M vs $1M.","Chris Smith appointed CEO effective Aug 15; Vishal Sikri named President, Pharma Services in May.","Cash and securities $466M; company launched enterprise-wide performance improvement plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-22-000132","json":"https://secwatch.observer/filing/0001077183-22-000132.json","markdown":"https://secwatch.observer/filing/0001077183-22-000132.md","text":"https://secwatch.observer/filing/0001077183-22-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/0001077183-22-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/neo-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:46:04.257658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}